eCAM Advance Access originally published online on February 7, 2006
eCAM 2006 3(1):25-30; doi:10.1093/ecam/nek022
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Review |
Regulatory T Cells, a Potent Immunoregulatory Target for CAM Researchers: The Ultimate Antagonist (I)
Immunosciences Laboratory, Inc. 8693 Wilshire Boulevard, Suite 200, Beverly Hills, CA 90211, USA
Over the past decade, great interest has been given to regulatory T (Treg) cells. A vast body of evidence has shown the existence and highlighted the importance of Treg cells in the active suppression of immune system responses. This form of immunoregulation is the dominant means utilized by the immune system to reach a harmony between reciprocal response processes in order to ensure adequate host defense with minimal host detriment. Therapeutically targeting Treg cells is a direct and powerful means to manipulate the immune system to achieve beneficial effects on various disease pathologies, including allergy, autoimmunity and cancer, as well as the facilitation of organ transplantation. This powerful target for immunoregulation is of much concern to practitioners and researchers of complementary and alternative medicine because it allows a great deal of control and certainty in dealing with the prevalence of debilitating immune system-related disorders for which there has been little remedy outside of Western Medicine.
Keywords: immune system modulation – regulatory T cells – Treg
For reprints and all correspondence: Aristo Vojdani, Immunosciences Laboratory, Inc., Section of Neuroimmunology, 8693 Wilshire Boulevard, Suite 200, Beverly Hills, CA 90211, USA. E-mail: immunsci{at}ix.netcom.com
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
P. Correale, P. Tagliaferri, A. Fioravanti, M. T. Del Vecchio, C. Remondo, F. Montagnani, M. S. Rotundo, C. Ginanneschi, I. Martellucci, E. Francini, et al. Immunity Feedback and Clinical Outcome in Colon Cancer Patients Undergoing Chemoimmunotherapy with Gemcitabine + FOLFOX followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Aldesleukin (GOLFIG-1 Trial) Clin. Cancer Res., July 1, 2008; 14(13): 4192 - 4199. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Yamaguchi, T. Takahashi, M. Sakuma, T. Sugita, K. Uchikawa, S. Sakaihara, T. Kanda, M. Arai, and K. Kawakita Acupuncture Regulates Leukocyte Subpopulations in Human Peripheral Blood Evid. Based Complement. Altern. Med., December 1, 2007; 4(4): 447 - 453. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Bellavite, R. Ortolani, F. Pontarollo, V. Piasere, G. Benato, and A. Conforti Immunology and Homeopathy. 4. Clinical Studies--Part 1 Evid. Based Complement. Altern. Med., September 1, 2006; 3(3): 293 - 301. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Vojdani and J. Erde Regulatory T Cells, a Potent Immunoregulatory Target for CAM Researchers: Modulating Tumor Immunity, Autoimmunity and Alloreactive Immunity (III) Evid. Based Complement. Altern. Med., September 1, 2006; 3(3): 309 - 316. [Abstract] [Full Text] [PDF] |
||||

